Vilglad (Vildagliptin)

Vilglad (Vildagliptin) is a prescription oral antidiabetic medication belonging to the dipeptidyl peptidase-4 (DPP-4) inhibitor class, specifically designed to improve glycemic control in adults with type 2 diabetes mellitus. This advanced medication works by blocking the DPP-4 enzyme, which naturally breaks down incretin hormones like GLP-1 and GIP. By preserving these hormones, Vilglad enhances your pancreas's ability to release insulin in response to meals while simultaneously reducing excessive glucose production by the liver, resulting in superior blood sugar regulation.

Vilglad offers a distinctive clinical advantage as a weight-neutral diabetes management option with a significantly lower risk of hypoglycemia compared to many alternative antidiabetic agents. It provides balanced control of both fasting glucose levels and post-prandial (after-meal) blood sugar spikes, making it an effective monotherapy choice for patients unable to tolerate metformin, as well as a reliable add-on therapy when combined with metformin, sulfonylureas, thiazolidinediones, or insulin regimens.

The standard dosage of Vilglad is typically 50 mg once or twice daily, with a maximum recommended dose of 100 mg per day. It may be taken with or without food, though dosing should always be determined and monitored by your healthcare provider based on individual therapeutic needs and renal function.

Vilglad is widely recognized and recommended in comprehensive diabetes management guidelines as a safe, effective add-on therapy for patients requiring improved HbA1c control with minimal adverse effects and a favorable safety profile.